MARKET WIREYahoo Finance • 20h ago
Chesnara (LSE:CSN) Stock Could Be Fully Valued On Its Sales BaseYahoo Finance report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
Why SEPN Stock slipped -1.82% Today — RQD Quant Desk Flash
$43.20 -1.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $42.98
Septerna Inc. (SEPN) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $2.05B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SEPN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SEPN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Septerna Inc. (NASDAQ: SEPN) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $43.20 (-1.82% 1D, market cap $2.05B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, SEPN ranks #140 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SEPN compare to SDGR and MRVI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SEPN carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.7%. By comparison, SDGR (Schrodinger Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and MRVI (Maravai LifeSciences Holdings Inc. (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, SEPN leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SEPN?
▼
Per SEPN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001984086), Septerna Inc. generated $46.0M in revenue (+4174.5% YoY), -$48.9M in net income, and $109.7M in free cash flow against $596.2M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $42.98 (-0.52%)🧬 Disciplined Float (-0.12% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 238.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+2.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SEPN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY SEPN SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)
Altman Z-Score 5.87 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)
Disciplined Float (-0.12% YoY Shares) & executive Form 4 sales trim 12 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$36.42+8% Next Q
55
Q2 (-2Q)Grade C$39.35+12.2% Next Q
58
Q3 (-1Q)Grade C$44.14-2.1% Next Q
60
CurrentGrade C$43.20+0.9% Hist 90D α
63
Trajectory: C (55) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the SEPN Bull Thesis Could Fail
Even with a 63/100 (C) score, SEPN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.12% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($39.13) or 200D SMA ($32.26) invalidates the momentum regime and cuts Target Base ($44.17) toward Bear Floor ($34.45).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SEPN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SEPN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SEPN Stock slipped -1.82% Today — RQD Quant Desk Flash
Septerna Inc. (SEPN) slipped -1.82% to $43.20, trading at 76% of its 52-week range ($17.55 – $51.1). Solid steady margins (-21% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 76% of its 52-week range ($17.55 – $51.1) with RSI-14 at 62.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $43.20 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $109.7M annual free cash flow.
Live SEPN Headlines & Catalysts
MARKET WIREInvesting.com UK • 23h ago
Septerna president and COO Elizabeth Bhatt sells $149,644 in stock By Investing.comInvesting.com UK report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMilk Road • 1d ago
Septerna, Inc. (SEPN)Milk Road report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
CATALYSTTipRanks • 1d ago
3 Small-Cap Stocks Analysts Expect to Rally over 35%TipRanks report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 5d ago
Is Septerna (SEPN) Stock Too Rich, Or Still Reasonable?Septerna has delivered a sharp share-price run over the past year, and that leaves investors asking whether the current market value is adequately grounded in its sales. With the stock now drawing more attention, the key
MARKET WIREYahoo Finance • 49d ago
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?Septerna (SEPN) heads into a busy conference stretch, with investor attention drawn to upcoming presentations at Wells Fargo’s 21st Annual Healthcare Conference on September 8 and Cantor Fitzgerald’s Global Healthcare Co
MARKET WIREYahoo Finance • 53d ago
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s commo
MARKET WIREYahoo Finance • 69d ago
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announc
CATALYSTYahoo Finance • 84d ago
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue EstimatesYahoo Finance coverage on SEPN stock catalysts, institutional flow, and earnings outlook.
RISK WATCHYahoo Finance • 120d ago
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?Septerna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (SEPN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SEPN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +74.05%⚡ TESTING RESISTANCE
2026-11-03O $45.23H $45.23L $43.20C $43.20VOL 223.5K
RES: $45.30SUP: $33.47SMA50: $39.13SMA200: $32.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SEPN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SEPN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SEPN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SEPN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SEPN)
Health Care Rank #140 of 1016
⚔️ SDGR vs SEPN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SEPN vs. SDGR, MRVI, ZYME, PVLA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Septerna Inc. (SEPN) ranks #140 by composite RQD confidence (63/100, grade C) and #251 by equity capitalization ($2.05B). Within this direct 5-issuer industry benchmark cohort, SEPN leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SEPN
ACTIVE
Septerna Inc. | C | 63/100 | — | — | -20.7% | -1.82% | $2.05B | Benchmark Subject |
| SDGR Schrodinger Inc. | D+ | 53/100 | — | 55.7% | -35.0% | -3.50% | $2.03B | /sdgr-vs-sepn → |
| MRVI Maravai LifeSciences Holdings Inc. (Class A) | D- | 37/100 | — | 18.3% | -35.0% | -7.94% | $2.03B | /mrvi-vs-sepn → |
| ZYME Zymeworks Inc. | D | 50/100 | — | — | -32.2% | +1.33% | $2.02B | /zyme-vs-sepn → |
| PVLA Palvella Therapeutics Inc. | D | 45/100 | — | — | -27.9% | +0.12% | $2.11B | /pvla-vs-sepn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001984086In its most recent audited fiscal period (FY2025, filed 2025-12-31), Septerna Inc. (SEPN) reported GAAP revenue of $46.0M (+4174.5% vs. FY2024 revenue of $1.1M , and +30331.1% cumulative change since FY2023) , GAAP net income of -$48.9M, operating cash flow of $110.2M, and free cash flow of $109.7M (+257.6% YoY). On the balance sheet, SEPN closed FY2025 with $596.2M in total assets against $0 in total debt (Altman Z-Score: 5.87, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $46.0M | -$48.9M | $110.2M | $109.7M | $596.2M | — |
| FY2024 (FY) | 2024-12-31 | $1.1M | -$71.8M | -$67.5M | -$69.6M | $456.6M | — |
| FY2023 (FY) | 2023-12-31 | $151.0K | $4.2M | -$38.7M | -$38.7M | — | — |
3. SEPN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SEPN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Septerna Inc. (NASDAQ: SEPN) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $43.20 (-1.82% 1D, market cap $2.05B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, SEPN ranks #140 in composite RQD confidence.
How does SEPN compare to SDGR and MRVI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SEPN carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.7%. By comparison, SDGR (Schrodinger Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and MRVI (Maravai LifeSciences Holdings Inc. (Class A)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, SEPN leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SEPN?
Per SEPN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001984086), Septerna Inc. generated $46.0M in revenue (+4174.5% YoY), -$48.9M in net income, and $109.7M in free cash flow against $596.2M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SEPN trading relative to its 50-day, 200-day, and 52-week technical levels?
SEPN last traded at $43.20 (-1.82% on volume of 475,347 shares), positioning the stock +10.40% above its 50-day simple moving average ($39.13) and +33.91% above its 200-day simple moving average ($32.26). Across its 52-week range of $17.55 to $51.10, SEPN sits at the 76.5% percentile with a 14-day RSI of 62.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($37.80 to $48.60).
ROARABLE RATING BRIEF • RQD 63/100 (C)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SEPN — Septerna Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:41Z
1. Roarable Rating Brief: What This Means to a Prospective Investor
SEPN scores 63 out of 100, grade C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:
- Fundamental Cash Engine (13/20): Reflects ROIC of -20.7% and an FCF yield of 5.19%. For a prospective investor, the negative ROIC signals that invested capital is not currently earning a return, while the positive FCF yield indicates the cash-generation picture is less negative than the earnings picture.
- Whale 13F Flow (16/20): Reflects institutional accumulation and options positioning.
- Insider Conviction (8/20): Reflects SEC Form 4 and Congressional PTR cluster flow. This is the weakest pillar and is the area where the source data gives the least supportive signal.
- Macro Regime Fit (12/20): Reflects beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity to broad moves rather than amplified volatility.
- Forensic Balance Sheet (14/20): Reflects Altman Z-Score of 5.87, Piotroski F-Score of 6/9, and Debt/Equity of 0.5. These are the most supportive metrics in the rating and point to a balance sheet that the rating treats as relatively sound.
Taken together, the upside drivers are the institutional flow and balance-sheet strength; the valuation and profitability tradeoffs are negative ROIC and operating losses; and the insider pillar is a neutral-to-negative reading. The rating's "Hold" verdict reflects this balance rather than a directional call.
2. Business Model, Unit Margins & SEC Financial Trajectory
Septerna Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile identifies a market capitalization of $2.1B. FY 2025 revenue was $46.
Revenue grew from $0.2M in FY 2023 to $1.1M in FY 2024 and $46.0M in FY 2025, while operating losses were -$80.8M in FY 2024 and -$68.3M in FY 2025. Per the market data, the operating margin and net margin are both -60%, the gross margin is 0%, and ROIC is -20.7%. The Piotroski F-Score is 6/9 and the Altman Z-Score is 5.87, which the rating treats as supportive of balance-sheet resilience. Debt/Equity is 0.5. Cash was $120.7M at FY 2025 versus $238.2M at FY 2024.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Institutional flow (16/20) and a strong forensic balance sheet (Altman Z 5.87, Piotroski F 6/9) support the rating despite negative ROIC. With Fundamental Cash Engine at 13/20 (ROIC -20.7%, FCF yield 5.19%) and Institutional Whale Flow at 16/20, sustained execution supports upside toward the top of the $17.55 – $51.10 52-week range.
- 🐻 Primary Bear Case: ROIC of -20.7%, operating margin of -60%, and an insider pillar of only 8/20 show weak profitability and limited insider conviction. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The source data therefore does not establish upstream or downstream dependencies, sector correlations, or second-order bottlenecks for SEPN. The sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is the only contextual link available.
- Key Question #1: What products or pipeline assets generate the FY 2025 revenue of $46.0M, and what is its customer base?
- Key Question #2: What is the context of the president and COO's $149,644 stock sale and whether other insiders are trading in the same direction?
- Key Question #3: How sensitive is SEPN's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?
SEPN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Septerna Inc. (SEPN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 20h ago
Chesnara (LSE:CSN) Stock Could Be Fully Valued On Its Sales Base Yahoo Finance report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 23h ago
Septerna president and COO Elizabeth Bhatt sells $149,644 in stock By Investing.com Investing.com UK report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Milk Road • 1d ago
Septerna, Inc. (SEPN) Milk Road report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TipRanks • 1d ago
3 Small-Cap Stocks Analysts Expect to Rally over 35% TipRanks report covering Septerna Inc. (SEPN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 5d ago
Is Septerna (SEPN) Stock Too Rich, Or Still Reasonable? Septerna has delivered a sharp share-price run over the past year, and that leaves investors asking whether the current market value is adequately grounded in its sales. With the stock now drawing more attention, the key
🟡 MARKET WIRE Yahoo Finance • 49d ago
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich? Septerna (SEPN) heads into a busy conference stretch, with investor attention drawn to upcoming presentations at Wells Fargo’s 21st Annual Healthcare Conference on September 8 and Cantor Fitzgerald’s Global Healthcare Co
🟡 MARKET WIRE Yahoo Finance • 53d ago
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s commo
🟡 MARKET WIRE Yahoo Finance • 69d ago
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announc
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SEPN Bull vs. Bear Conversation Board — What's Your Call at $43.20?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SEPN 🐻 33% BEARISH CONVICTION
CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $52.80 (+20.0%)
📌 Pinned Debate Institutional flow (16/20) and a strong forensic balance sheet (Altman Z 5.87, Piotroski F 6/9) support the rating despite negative ROI
Long SEPN at $44.00 targeting $52.80. Institutional flow (16/20) and a strong forensic balance sheet (Altman Z 5.87, Piotroski F 6/9) support the rating despite negative ROIC.. Institutional whale score is 16/20 and the risk/reward vs. the $17.55 52-week low is skewed heavily in favor of bulls.
EarningsSniper 🐂 BULL
Both sides have a point here — SEPN's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RE RedlineAuditor Accounting Quality Watch 🐻 BEARISH
🎯 Target: $34.32 (-22.0%)
Spot @ $44.00 ROIC of -20.7%, operating margin of -60%, and an insider pillar of only 8/20 show weak profitability and limited insider conviction.
Here is the bear case nobody on the bull side wants to address on SEPN: ROIC of -20.7%, operating margin of -60%, and an insider pillar of only 8/20 show weak profitability and limited insider conviction.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.